Bausch + Lomb to Resume Intraocular Lens Sales Following March Recall

Bausch + Lomb will restart sales of its intraocular lenses after identifying a raw material from a vendor as the source of toxic anterior segment syndrome (TASS) cases that led to a voluntary recall in March. The recall included Envista Envy, Envista Aspire, and some Envista monofocal lenses. Although the products were off the market for only a few weeks, some surgeons remain cautious. The company traced 90% of adverse reports to the suspect material, prompting confidence in resuming distribution in the U.S. within weeks. International relaunches will be coordinated with health authorities. TASS reporting spiked in late 2024 but remained below industry averages. Analysts estimate $70–$90 million in potential revenue risk for 2025 and foresee modest headwinds in Bausch + Lomb’s surgical division. Competitor Alcon may have benefited from the pause, especially with the timing of its Panoptix Pro launch. Bausch + Lomb plans an aggressive re-entry strategy.

11-05-2025